Сравнение

Glepaglutide vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

нет данных

396091-73-9

Молекулярная масса

нет данных

1047.21 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Glepaglutide	Pasireotid
Германия	Не одобрено	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Glepaglutide and Pasireotid?: Glepaglutide is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Pasireotid?: The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Pasireotid in Germany and the United States?: Германия: Glepaglutide — Не одобрено, Pasireotid — Рецептурный. США: Glepaglutide — Не одобрено, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Pasireotid

Германия

Не одобрено

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Glepaglutide and Pasireotid?

Glepaglutide is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Pasireotid?

The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Pasireotid in Germany and the United States?

Германия: Glepaglutide — Не одобрено, Pasireotid — Рецептурный. США: Glepaglutide — Не одобрено, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.